X4 Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from X4 Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 2,142% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-30.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 64% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-86.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 81% of Healthcare companies in United States.
Cash Cushion Ratio
+55%Cash, after subtracting all debt, equals 55% of its market value (net cash).
Higher than 78% of Healthcare companies in United States.
Tangible Assets Ratio
91%Of every $100 the company owns, $91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 63% of Healthcare companies in United States.
Tangible Net Worth Ratio
86%Of every $100 of net worth, $86 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 66% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
X4 Pharmaceuticals, Inc. owes $0.39 for every $1 it owns. X4 Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
160.0Investors pay $160.0 for every $1 of X4 Pharmaceuticals, Inc.'s yearly profit, higher than 95% of Healthcare companies in United States.
P/B ratio
2.04The share price is 2.04 times X4 Pharmaceuticals, Inc.'s book value per share, lower than 58% of Healthcare companies in United States.
Market cap
$317 MThe total market value of all of X4 Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$155 MWhat X4 Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.57Net worth divided by the number of shares. The share price of $3.20 is 2.0 times this, which is the P/B above.
Return on equity (ROE)
-113.1%X4 Pharmaceuticals, Inc. lost 113.1% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
Owes vs Owns
0.39×X4 Pharmaceuticals, Inc. owes $0.39 for every $1 it owns (low), lower than 53% of Healthcare companies in United States.
Dividend yield
NoneX4 Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+1273%Revenue rose 1273% in the year to Dec 2025.
Profit growth
LossX4 Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-225.6%X4 Pharmaceuticals, Inc. lost $226 for every $100 of revenue.
Interest cover
Not coveredX4 Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashX4 Pharmaceuticals, Inc. held $176 M more cash than debt (net cash) at Dec 2025.
Questions
What is X4 Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $160.0 for every $1 of X4 Pharmaceuticals, Inc.'s yearly profit, higher than 95% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For X4 Pharmaceuticals, Inc.: $317 M ÷ $155 M (30 Jun 2026) = 2.0.
What is X4 Pharmaceuticals, Inc.'s return on equity?
X4 Pharmaceuticals, Inc. lost 113.1% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
How much does X4 Pharmaceuticals, Inc. owe compared with what it owns?
X4 Pharmaceuticals, Inc. owes $0.39 for every $1 it owns (low), lower than 53% of Healthcare companies in United States.
Does X4 Pharmaceuticals, Inc. pay a dividend?
No. X4 Pharmaceuticals, Inc. does not currently pay a dividend.
Is X4 Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 1273% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.